BATF2 and nasopharyngeal carcinoma: The IHC microarray showed that 63/129 (48.83%) cases were BATF2-positive, with BATF2 predominately expressed in the nucleus of NPC cells (Figure 1A) and elevated BATF2 expression scores in stage I-II NPC patients and those without recurrent tumor or metastasis in the cervical lymph nodes (Figure 1B).